Curis (FRA:CUS0) Additional Paid-In Capital : €1,119.96 Mil(As of Mar. 2024)

View and export this data going back to . Start your Free Trial

What is Curis Additional Paid-In Capital?

Curis's quarterly additional paid-in capital declined from Sep. 2023 (€1,137.64 Mil) to Dec. 2023 (€1,114.88 Mil) but then increased from Dec. 2023 (€1,114.88 Mil) to Mar. 2024 (€1,119.96 Mil).

Curis's annual additional paid-in capital increased from Dec. 2021 (€1,046.27 Mil) to Dec. 2022 (€1,128.73 Mil) but then declined from Dec. 2022 (€1,128.73 Mil) to Dec. 2023 (€1,114.88 Mil).

Curis Additional Paid-In Capital Historical Data

The historical data trend for Curis's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Curis Additional Paid-In Capital Chart

Curis Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Additional Paid-In Capital

Get a 7-Day Free Trial

884.46

967.20

1,046.27

1,128.73

1,114.88

Curis Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Additional Paid-In Capital	Get a 7-Day Free Trial															1,117.22	1,105.52	1,137.64	1,114.88	1,119.96

Curis Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital

(Issue Price

Par Value)

Shares Outstanding (Diluted Average)

Curis Additional Paid-In Capital Related Terms

Thank you for viewing the detailed overview of Curis's Additional Paid-In Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

Curis (FRA:CUS0) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Curis Inc (FRA:CUS0) » Definitions » Additional Paid-In Capital

Comparable Companies

Traded in Other Exchanges

CRIS:USA

Address

128 Spring Street, Building C - Suite 500, Lexington, MA, USA, 02421

Website

https://www.curis.com

Curis Inc is a biotechnology company that develops and commercializes innovative drugs and therapies in the immuno-oncology and precision oncology therapeutic areas. The company targets solid tumors, diffuse large B-cell lymphoma, advanced solid tumors or lymphomas, hematological cancers, and others. Its pipeline products include Fimepinostat, CA-170, CA-4948, CA-327, and Erivedge.

Curis (FRA:CUS0) Headlines

No Headlines